How to Get Jardiance in Michigan: Prescriptions, Telehealth, and Pharmacy Access

What Is Jardiance and Why Is It Prescribed?

Jardiance is the brand name for empagliflozin, an SGLT2 inhibitor manufactured by Boehringer Ingelheim and Eli Lilly. It blocks the sodium-glucose co-transporter 2 in the proximal tubule of the kidney, causing glucose excretion in urine and reducing blood sugar without stimulating insulin secretion. The FDA has approved three distinct indications: glycemic control in adults with type 2 diabetes, reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and reduction of hospitalizations and cardiovascular death in adults with heart failure [1].

In 2023, the FDA expanded approval to include chronic kidney disease (CKD) with or without type 2 diabetes, making empagliflozin one of the few oral agents with a dedicated CKD label [1]. The EMPA-KIDNEY trial (N=6,609) demonstrated a 28% relative risk reduction in kidney disease progression or cardiovascular death compared with placebo (P<0.001) [2].

The drug comes as 10 mg and 25 mg tablets taken once daily in the morning, with or without food. For cardiovascular and renal protection, the 10 mg dose is typically sufficient; the 25 mg dose is reserved for patients needing additional glycemic lowering [1].

The Clinical Evidence Behind Empagliflozin

Empagliflozin's approval history rests on some of the most cited cardiovascular outcome trials in modern endocrinology. The EMPA-REG OUTCOME trial (N=7,020) published in the New England Journal of Medicine in 2015 showed a statistically significant 14% relative risk reduction in 3-point major adverse cardiovascular events (MACE), cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, compared with placebo in patients with type 2 diabetes and high cardiovascular risk [3]. Cardiovascular mortality alone fell by 38% relative to placebo [3].

"Empagliflozin, added to standard care, significantly reduced the risk of major adverse cardiovascular events," wrote Zinman et al. in the original EMPA-REG OUTCOME paper [3].

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo (hazard ratio 0.75 to 95% CI 0.65, 0.86, P<0.001) in patients with heart failure with reduced ejection fraction [4]. EMPEROR-Preserved (N=5,988) extended this benefit to heart failure with preserved ejection fraction, a population with historically limited pharmacologic options [5].

The American Diabetes Association's Standards of Care in Diabetes recommend SGLT2 inhibitors for patients with type 2 diabetes who also have established cardiovascular disease, heart failure, or CKD, irrespective of baseline HbA1c [6]. The 2022 AHA/ACC guideline for heart failure similarly lists empagliflozin as a Class I recommendation for patients with HFrEF [7].

These outcomes explain why Michigan clinicians, and increasingly, Michigan telehealth providers, prescribe empagliflozin not just for sugar control but as a cardiorenal protective agent.

How to Get a Jardiance Prescription in Michigan

Getting a Jardiance prescription in Michigan requires a licensed prescriber to evaluate your clinical history, review relevant labs, and determine that empagliflozin is appropriate for at least one FDA-approved indication. Michigan law does not mandate an in-person visit for a telehealth prescription. Under MCL 333.16285, a Michigan-licensed prescriber may establish a valid patient-prescriber relationship via synchronous audio-video telehealth, which is sufficient to generate a controlled or non-controlled prescription [8].

The practical pathway looks like this:

1. Schedule a visit, in person with a primary care physician, endocrinologist, or cardiologist, or via a Michigan-licensed telehealth platform with synchronous video capability.
2. Provide medical history, existing diagnoses (type 2 diabetes, heart failure, CKD), current medications, and any prior SGLT2 inhibitor use.
3. Obtain baseline labs, at minimum, a comprehensive metabolic panel covering serum creatinine and eGFR; an HbA1c if the indication is glycemic control.
4. Receive the prescription electronically, Michigan participates in the Interstate Medical Licensure Compact, allowing many out-of-state telehealth providers to hold a Michigan license and e-prescribe directly to Michigan pharmacies.
5. Choose your pharmacy, a retail chain, independent pharmacy, mail-order pharmacy, or a licensed 503A compounding pharmacy in Michigan.

Most telehealth appointments for a straightforward empagliflozin request last 15 to 30 minutes. Prescription transmission is electronic and reaches a Michigan pharmacy the same day in most cases [8].

Labs Required Before Starting Jardiance in Michigan

A baseline eGFR is non-negotiable. Because empagliflozin's efficacy depends on kidney function, the FDA label specifies that the drug is not recommended for glycemic control when eGFR falls below 30 mL/min/1.73 m², and should not be initiated for any indication when eGFR is <20 mL/min/1.73 m² [1]. Michigan clinicians, whether in-person or telehealth, will order or request documentation of a recent renal panel before writing the prescription.

A complete metabolic panel covering glucose, electrolytes, BUN, and creatinine is standard. For patients with type 2 diabetes, an HbA1c within the past three months satisfies most prior authorization requirements. A urinalysis with a spot urine albumin-to-creatinine ratio (UACR) is frequently ordered when CKD is the indication, both to establish baseline albuminuria and to satisfy payer documentation requirements.

Patients on diuretics or ACE inhibitors/ARBs should have potassium checked before starting, since empagliflozin has a modest diuretic effect that could affect electrolyte balance. The FDA label does not mandate a fasting lipid panel, but many Michigan Medicaid prior authorization forms require recent A1c and renal function documentation [1].

The American Diabetes Association recommends monitoring eGFR at least annually in patients on SGLT2 inhibitors, or every 3 to 6 months if eGFR is between 20 and 45 mL/min/1.73 m² [6].

Telehealth Prescribing for Jardiance in Michigan

Michigan is one of the most telehealth-permissive states in the Midwest. Synchronous audio-video visits satisfy the patient-prescriber relationship requirement under Michigan law, meaning a legitimate telehealth provider can prescribe empagliflozin after a single compliant visit without a prior in-person encounter [8].

Several national telehealth platforms hold Michigan prescribing licenses and routinely prescribe Jardiance for qualifying patients. These include endocrinology-focused services and metabolic health platforms that carry board-certified internists or endocrinologists on their clinical staff. HealthRX connects Michigan patients with licensed Michigan prescribers for empagliflozin evaluation as part of its cardiometabolic program.

The following framework captures what a Michigan telehealth visit for Jardiance typically covers:

Step 1, Indication review. The prescriber confirms at least one FDA-approved indication: type 2 diabetes with or without cardiovascular disease, heart failure (HFrEF or HFpEF), or CKD.

Step 2, Contraindication screening. History of recurrent genital mycotic infections, Fournier gangrene, diabetic ketoacidosis (DKA), severe renal impairment (eGFR <20), and known hypersensitivity to empagliflozin are all screened.

Step 3, Drug interaction review. Concurrent insulin or sulfonylurea use raises hypoglycemia risk; dose reductions of those agents may be needed. Loop diuretic combinations require monitoring for volume depletion.

Step 4, Lab verification. The prescriber reviews labs submitted by the patient or orders them through a partner lab network before transmitting the prescription.

Step 5, Prescription routing. The e-prescription goes directly to the patient's preferred Michigan pharmacy or a mail-order pharmacy the platform has contracted with.

A Michigan telehealth provider may not prescribe empagliflozin via asynchronous questionnaire alone; Michigan law requires real-time, two-way audio-video communication for prescription issuance [8].

Michigan Medicaid and Insurance Coverage for Jardiance

Michigan Medicaid (Healthy Michigan Plan and traditional Medicaid) covers empagliflozin for all three FDA-approved indications, but prior authorization is required in every case. The PA criteria for type 2 diabetes typically require documentation of HbA1c above 7.0%, current use of metformin (or a documented contraindication), and confirmation of Michigan Medicaid enrollment. Heart failure and CKD indications require an ejection fraction measurement or documented eGFR below 60 mL/min/1.73 m², respectively.

Commercial insurers in Michigan, including Blue Cross Blue Shield of Michigan, Priority Health, and McLaren Health Plan, generally tier Jardiance as a Tier 3 or Tier 4 drug. Out-of-pocket costs without assistance can reach $550, $600 per month for the brand-name product. Boehringer Ingelheim's Jardiance Savings Card reduces cost-sharing to as low as $10 per 30-day supply for commercially insured patients who qualify [9].

Medicare Part D coverage of Jardiance varies by plan formulary. As of 2025, the Inflation Reduction Act's out-of-pocket cap of $2,000 annually applies to Medicare beneficiaries, meaningfully reducing Jardiance costs for older Michigan patients. Patients enrolled in Medicare Extra Help (Low Income Subsidy) pay nominal copays.

For patients whose commercial prior authorization is denied, Michigan law requires insurers to provide a written denial with the specific clinical criteria that were not met, and patients have the right to an expedited appeal within 72 hours for urgent clinical situations.

Who Can Prescribe Jardiance in Michigan?

Any Michigan-licensed prescriber with prescriptive authority can write a Jardiance prescription. That includes MDs, DOs, nurse practitioners (NPs), physician assistants (PAs), and clinical nurse specialists who hold DEA registration where relevant and Michigan prescriptive authority. Jardiance is not a controlled substance, so DEA registration is not required; a standard Michigan prescriber license is sufficient [8].

NPs in Michigan hold full practice authority under the Public Health Code amendments effective in 2023, meaning they may independently evaluate patients and prescribe empagliflozin without physician oversight or a collaborative agreement. PAs in Michigan still operate under a supervising physician agreement for prescriptive authority, but that arrangement is standard practice and does not delay prescribing in routine cases.

Dentists, optometrists, and pharmacists in Michigan do not hold authority to initiate empagliflozin prescriptions, though Michigan-licensed pharmacists may collaborate with physicians under collaborative practice agreements for medication therapy management that includes SGLT2 inhibitors.

503A Compounding Pharmacies in Michigan

503A pharmacies compound drugs for individual patients based on a valid, patient-specific prescription. In Michigan, licensed 503A compounding pharmacies may prepare empagliflozin in non-commercially available forms, for example, a lower-strength formulation for a patient with specific clinical needs, provided the prescription is not an exact copy of an FDA-approved commercially available product and meets patient-specific need criteria [10].

Empagliflozin is commercially available only as 10 mg and 25 mg oral tablets. A 503A pharmacy might compound a suspension or an alternative-strength capsule for a patient who cannot swallow tablets or who has a prescriber-documented need outside the commercial dosage range. Michigan's Bureau of Professional Licensing oversees 503A pharmacy compliance with both state pharmacy rules and USP Chapter 795 standards [10].

Patients considering a 503A source should confirm that the pharmacy holds an active Michigan pharmacy license. The FDA does not approve 503A-compounded products, so these formulations lack the bioequivalence data of the commercial Jardiance tablet. Most Michigan clinicians default to the commercial product unless a specific clinical barrier exists.

How Long Until You Receive Jardiance in Michigan?

Timing depends on the route. A same-day in-person visit to a Michigan physician or urgent care clinic with the appropriate clinical setup can generate an e-prescription within hours; a local Michigan pharmacy can dispense the commercial tablet the same day if it is in stock. CVS, Walgreens, Meijer, and Kroger locations across Michigan routinely stock both the 10 mg and 25 mg strengths.

Telehealth pathways add one or two steps. A synchronous video visit itself may conclude with same-day prescription transmission. If the prescriber requires labs before transmitting, a patient who uses a LabCorp or Quest location in Michigan and opts for expedited processing can receive results within 24 hours, placing total time from visit to prescription at 2, 3 business days. Mail-order pharmacy shipping typically adds 3, 5 business days.

Prior authorization, when required, is the main delay. Michigan Medicaid PA requests can take 3, 14 business days under standard review. Most commercial insurers process standard PA requests within 3, 5 business days. An expedited PA, which Michigan insurers must process within 72 hours for urgent cases, can compress this significantly.

Patients who need medication quickly may ask their prescriber to issue a 30-day emergency supply at the pharmacy while the PA is pending, a practice explicitly permitted under Michigan insurance regulations.

Transferring a Jardiance Prescription to Michigan

Patients relocating to Michigan from another state can transfer a Jardiance prescription if it was issued by a prescriber licensed in the originating state and the prescription has remaining refills. Michigan pharmacy law generally allows one transfer of a non-controlled prescription between pharmacies. If the original prescription has no refills remaining, the patient needs a new prescription from a Michigan-licensed prescriber, either in person or via telehealth [8].

Out-of-state prescriptions written by providers who hold Michigan telehealth licenses through the Interstate Medical Licensure Compact (IMLC) are valid at Michigan pharmacies without any transfer process; they were issued under Michigan licensure to begin with. Patients moving from states outside the IMLC may encounter a brief gap requiring a new Michigan prescriber evaluation, which a telehealth platform can typically schedule within 24 to 48 hours.

A pharmacist in Michigan cannot independently substitute a compounded empagliflozin product for a commercial Jardiance prescription without explicit prescriber authorization, per Michigan pharmacy substitution rules.

Starting and Monitoring Empagliflozin in Michigan

The FDA-approved starting dose is 10 mg once daily, taken in the morning regardless of meals [1]. For patients with type 2 diabetes requiring additional glycemic lowering whose eGFR is at or above 45 mL/min/1.73 m², the dose may be increased to 25 mg once daily after a clinical reassessment [1]. For heart failure and CKD indications, the 10 mg dose is used across the labelled eGFR range above 20 mL/min/1.73 m².

Monitoring after initiation includes:

• eGFR and serum creatinine at 4 to 8 weeks after initiation, then annually (or every 3 to 6 months if baseline eGFR is 20, 45) [6].
• HbA1c every 3 months until target is reached, then every 6 months for patients with diabetes [6].
• Blood pressure check at follow-up, since empagliflozin reduces systolic BP by roughly 3 to 5 mmHg through osmotic diuresis [3].
• Genital hygiene counseling at every visit; genital mycotic infections occurred in 5.4% of women and 3.1% of men on empagliflozin versus lower rates on placebo in EMPA-REG OUTCOME [3].

Patients should be counseled to hold empagliflozin 3 to 4 days before elective surgery or prolonged fasting to reduce the small but real risk of euglycemic DKA, a condition where ketoacidosis occurs without markedly elevated glucose, a recommendation included in the 2023 American Diabetes Association Standards of Care [6].

The FDA also requires a warning about lower-limb amputations observed with canagliflozin (another SGLT2 inhibitor) in the CANVAS trial; the signal was not statistically significant for empagliflozin in EMPA-REG OUTCOME, but clinicians are advised to monitor patients with peripheral vascular disease [1] [3].

The DECLARE-TIMI 58 trial with dapagliflozin (N=17,160) confirmed class-level cardiovascular and renal benefits across SGLT2 inhibitors, supporting the generalizability of findings beyond individual drugs [11].

"SGLT2 inhibitors have moved well beyond glucose lowering; for patients with CKD and heart failure, the evidence base now matches or exceeds that for most drugs we have used for decades," wrote Perkovic et al. in the CREDENCE trial report in the New England Journal of Medicine [12].